Recently, the State Drug Administration approved the Class 1 innovative drug vorolanib tablets (trade name: Vomina) declared by Beda Pharmaceutical Co. The drug is used in combination with everolimus for patients with advanced renal cell carcinoma who have failed previous treatment with tyrosine kinase inhibitors.
Vorolanib is a multi-target receptor tyrosine kinase inhibitor with strong inhibitory effects on VEGFR2, KIT, PDGFR, FLT3 and RET, and exerts anti-tumor effects mainly by inhibiting neovascularization. The launch of this drug provides a new treatment option for patients with advanced renal cell carcinoma.
Vorolanib is a multi-target receptor tyrosine kinase inhibitor with strong inhibitory effects on VEGFR2, KIT, PDGFR, FLT3 and RET, and exerts anti-tumor effects mainly by inhibiting neovascularization. The launch of this drug provides a new treatment option for patients with advanced renal cell carcinoma.
